Loading…
S. 3788119th CongressPlaced on the calendarLatest action Jul 27, 2026Decoded by AI · checked against the record
The plain-language version leads. The official text is always the reference.
The CLEAR LABELS Act would require drug labels to name the actual manufacturing facility, not just the distributor.
40-second read · 4 questions answered below
This bill would require labels on active pharmaceutical ingredients and finished drugs to identify the "original manufacturer" — the last facility that did substantial manufacturing — along with a unique facility identifier. This information could appear on the label itself or be accessible via barcode, QR code, or online portal, with paper disclosure available on request. It also exempts compliant drugs from separate customs country-of-origin marking rules.
Drug manufacturers, packagers, and distributors would face new labeling and disclosure requirements, particularly those using overseas ingredients or manufacturing; pharmacists, doctors, and consumers would gain more visibility into drug origins.
Companies relying on foreign manufacturing or ingredients would need to change labeling practices and disclosure systems, and the FDA must first write implementing regulations before requirements take effect.
AI-drafted summary. Verify it against the official text before you act on it. Read the official bill on Congress.gov
Right now: it was placed on the Senate floor calendar, and the official record shows no floor action on it since. If the House changes it, it goes back to the Senate before reaching the President.
Latest action: — Placed on Senate Legislative Calendar under General Orders. Calendar No. 523.